Analyses by subgroups (prevalent diabetes, obesity or a combination of the two conditions) also demonstrated no effects of any of the types of n-3 fatty acid supplementation on plasma FGF23 levels over a 40-month period (data not shown). The gene discussed is FGF23; the disease is obesity disorder.